Hear Dr. Cosimo Spera, DecisionView's Head of Predictive Science, present a session called Predictive Analytics in Pharma: How to Improve the Drug Development Process. On average the drug development process spans over a ten years time period. It can be characterized into two phases: (a) pre-clinical and (b) clinical. The pre-clinical implies generally three to four years of knowledge and fact discovery to complete — no humans are involved — while the clinical phase, where humans are involved, follows three sub-phases. A phase four is possible after the drug has already been introduced to the market if more testing is required. The focus of this talk is on the "human" clinical phases from phase I to phase III. We will review the state of the art "predictive" models proposed to optimize the drug development process and discuss a few "real life" test cases.
Linda Drumright, DecisionView COO, chairs a session called Fostering Global Collaboration Through Adoption of a New Enrollment Planning Culture. During this session, speakers from Pfizer and GlaxoSmithKline discuss the challenges of implementing new solutions to improve the enrollment planning process; describe the value of utilizing data to drive strategic business decisions; and identify the value created by using a consistent and predictive analytical process for planning, forecasting, and adjusting clinical trial enrollment.
Dr. Cosimo Spera, PhD., DecisionView's Head of Predictive Modeling Sciences, presents From Present To Future: Shaping the Practices of Clinical Trials.
DecisionView COO Linda Drumright participates in a panel discussion entitled Impact of Game-Changing Technology at this day-long conference focused on painting a vision for drug development and in particular clinical operations.
The DecisionView Customer Advisory Board (CAB) brings together DecisionView's strategic customers and advisors with the company's executive team to discuss long term trends and market demands in clinical operations, and how DecisionView can and should assist in solving these problems.
Munther Baara, Director of R&D Clinical Business Systems & Processes at Pfizer/Wyeth presented "Addressing the Challenges of Implementing New Tools and Processes that Enable Transparency and Accountability in the Enrollment Planning Process". This session describes how Pfizer/Wyeth are executing on their global strategic vision to make measurable industry leading changes in the management of Trial Operations. They implemented a SaaS application (DecisionView StudyOptimizer) that uses predictive analytics to help model and adjust plans on the fly and collaborate across global teams. It allowed them to plan, forecast, track, model, analyze, and adjust clinical trial enrollment. This project utilizes an operational data warehouse as a common database layer to serve (transmit) data from several source systems (multiple enrollment systems, EDC tools and CTMS application) to the planning tool in a near real-time basis. The system is governed by the information domain stewards and guided by 2 principles: 1) One version of the truth 2) Collect data as close as possible to the source and fix data issues at the point of collection.
